H J Mann
Overview
Explore the profile of H J Mann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lupei M, Beilman G, Chipman J, Mann H
Chirurgia (Bucur)
. 2009 Dec;
104(5):575-81.
PMID: 19943557
Introduction: This study compares recent vasopressin use and outcomes to our early practice when vasopressin was introduced for septic shock. Methods: Charts of Surgical Intensive Care Unit (SICU) patients receiving...
2.
Kumar A, Mann H, Remmel R
J Vet Pharmacol Ther
. 2006 Nov;
29(6):587-9.
PMID: 17083465
No abstract available.
3.
Mann H
Crit Care Clin
. 2000 Nov;
16(4):641-58.
PMID: 11070809
This article takes a broad sweep at some of the forces that will impact pharmacy in the intensive care units of tomorrow. Each of the topics covered has journals or...
4.
Mann H, Wittbrodt E, Baghaie A, Cerra F
Pharmacotherapy
. 1998 Apr;
18(2):371-8.
PMID: 9545157
We compared pharmacokinetic parameters derived from three aminoglycoside serum concentration sampling methods and evaluated their effects on recommended aminoglycoside dosing regimens in 60 critically ill surgery patients. Patients had presumed...
5.
Wu F, Friend J, Lazar A, Mann H, Remmel R, Cerra F, et al.
Biotechnol Bioeng
. 1996 Oct;
52(1):34-44.
PMID: 18629850
A xenogeneic hollow fiber bioreactor utilizing collagen-entrapped dispersed hepatocytes has been developed as an extracorporeal bioartificial liver (BAL) for potential treatment of acute human fulminant hepatitis. Prolonged viability, enhanced liver-specific...
6.
Nyberg S, Mann H, Hu M, Payne W, Hu W, Cerra F, et al.
Drug Metab Dispos
. 1996 Jun;
24(6):643-8.
PMID: 8781779
Extrahepatic drug metabolism was studied in an anhepatic rabbit model. Plasma concentrations of 4-methylumbelliferone (4-MU) and its major metabolites, 4-methylumbelliferyl-O-glucuronide and 4-methyumbelliferyl sulfate, along with lidocaine and its major metabolites,...
7.
Hu M, Cipolle M, Sielaff T, Lovdahl M, Mann H, Remmel R, et al.
Crit Care Med
. 1995 Jul;
23(7):1237-42.
PMID: 7600833
Objectives: An extracorporeal bioartificial liver device must maintain viability and differentiated function of hepatocytes cultivated at high cell density. Growth factors, such as hepatocyte growth factor, found in high concentrations...
8.
Sielaff T, Hu M, Rao S, Groehler K, Olson D, Mann H, et al.
Transplantation
. 1995 May;
59(10):1459-63.
PMID: 7770934
Current bioartificial liver devices are based on the use of a large mass of hepatocytes exhibiting differentiated metabolic function. The pig has become a source of interest for the acquisition...
9.
Lazar A, Mann H, Remmel R, Shatford R, Cerra F, Hu W
In Vitro Cell Dev Biol Anim
. 1995 May;
31(5):340-6.
PMID: 7633671
The potential use of porcine hepatocytes in a bioartificial liver device requires large quantities of viable and highly active cells. To facilitate the scaling up of the system, liver specific...
10.
Nyberg S, Remmel R, Mann H, Peshwa M, Hu W, Cerra F
Ann Surg
. 1994 Jul;
220(1):59-67.
PMID: 8024360
Objective: Metabolic activity of transformed human liver (Hep G2) cells and primary rat hepatocytes were compared during in vitro application of a gel entrapment bioartificial liver. Background: Clinical trials of...